TheEdgeResearch
Home / Stocks / ADIA

Adia Med Inc. (ADIA)

OTC Healthcare Medical - Pharmaceuticals
$0.11 ▼ -1.79%
Market Cap
$10.4M
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
-8.23
52-Wk Range
0.025-0.278
CEO
Larry Powalisz
Country
US
Currency
USD

Adia Med Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Winter Park, FL, US. The stock last traded at $0.11, down 1.79% on the session, giving a market capitalisation of $10.4M. On trailing twelve-month figures it carries a trailing P/E of -0.03, a net margin of -56.5%. Its beta of -8.23 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.03
Price / Sales
14.82
Price / Book
-0.04
EV / EBITDA
-30.12
Gross margin
27.4%
Operating margin
-52.3%
Net margin
-56.5%
Return on equity
Debt / equity
-2.33
Current ratio
1.11
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
3
IPO date
2012-04-11
Headquarters
Winter Park, FL, US
About Adia Med Inc.

Adia Med Inc. is a publicly traded company dedicated to advancing regenerative medicine and healthcare innovation. The company operates through its primary divisions: Adia Med clinics and Adia Labs LLC. Adia Med clinics deliver specialized regenerative treatments, including stem cell therapies, while Adia Labs manufactures and distributes regenerative products. The company is also involved in multiple Institutional Review Board (IRB)-approved clinical studies.

Comparable companies

Adia Med Inc. is most often compared with the following Healthcare names:

ADHIAGSSAVVHETERHPILLZGIMVCONGRCPLTYFSHGI
More research on ADIA
ADIA technical analysis ADIA TheEdge Score Compare against peers
Open full interactive analysis & DCF →